Health Care & Life Sciences » Biotechnology | Gilead Sciences Inc.

Gilead Sciences Inc. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
11,221
24,890
32,037
30,317
26,135
22,214
Cost of Goods Sold (COGS) incl. D&A
2,899
3,895
4,117
4,398
4,512
4,853
Gross Income
8,322
20,995
27,920
25,919
21,623
17,361
SG&A Expense
3,662
5,698
6,329
7,927
7,299
8,254
EBIT
4,661
15,297
-
-
14,324
9,107
Unusual Expense
132
96
130
258
244
707
Non Operating Income/Expense
14
125
626
327
567
476
Interest Expense
307
412
688
964
1,118
1,077
Pretax Income
4,208
14,856
21,659
17,097
13,529
7,799
Income Tax
1,151
2,797
3,553
3,609
8,885
2,339
Consolidated Net Income
3,057
12,059
18,106
13,488
4,644
5,460
Net Income
3,075
12,101
18,108
13,501
4,628
5,455
Net Income After Extraordinaries
3,075
12,101
18,108
13,501
4,628
5,455
Net Income Available to Common
3,075
12,101
18,108
13,501
4,628
5,455
EPS (Basic)
1.81
7.35
11.91
9.94
3.51
4.17
Basic Shares Outstanding
1,529
1,522
1,464
1,339
1,307
1,298
EPS (Diluted)
1.81
7.35
11.91
9.94
3.51
4.17
Diluted Shares Outstanding
1,695
1,647
1,521
1,358
1,319
1,308
EBITDA
5,005
16,347
22,689
19,150
15,610
10,536
Minority Interest Expense
18
42
2
13
16
5

About Gilead Sciences

View Profile
Address
333 Lakeside Drive
Foster City California 94404
United States
Employees -
Website http://www.gilead.com
Updated 07/08/2019
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. It also offers other pharmaceutical products under the Letairis, Ranexa, AmBisome, and Zydelig brands.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.